Innovative medicines to treat oxygen radical mediated diseases

GenKyoTex
Chemin des Aulx 14
1228 Plan-Les-Ouates

Auf Karte anzeigen
Öffnungszeiten
MO - FR: 08:00 - 18:00
Firmenbeschrieb
GenKyoTex develops drugs against oxygen radical-mediated diseases such as age-related degenerative pathologies via a completely novel therapeutic pathway. Small molecules NOX inhibitors drugs target a novel family of enzymes so-called NADPH oxidases (NOX) and attack the problem at the source in a more specific manner as opposed to antioxidants.

„Für unsere Kunden sind wir einzigartig, weil GenKyoTex focuses on the specific inhibition of selected NOX enzymes to provide a major therapeutic gain to patients affected by age-related diseases. GenKyoTex has the lead in developing drugs for this new NOX pathway.“

Gründungsjahr
2006
 
Rechtsform
Kollektivgesellschaft
 
Anzahl Mitarbeiter
14
 
Umsatz
n/a CHF
 
Zielmärkte
Asien, Ganze Schweiz, USA/Kanada, Europa, Deutschland
 


Unser Team

Patrick Page

General Manager
CTO

patrick.page@genkyotex.com

Benoit Dubuis

CEO
CEO

bd@eclosion.ch

Jesus Martin-Garcia

Director
CFO

jmg@eclosion.ch
Schlüsselwörter
pharmaceutical biotech drug discovery
Marktleistungen
  • Small molecules NADPH oxidase inhibitors
    Current discovery projects in advanced stages include a number of proprietary chemical series with differential selectivity profile across NOX isoforms with potential in the treatment of cardiovascular and metabolic diseases.
Kernkompetenzen
  • Innovationskraft in der Entwicklung neuer Lösungen und Produkte
  • Intensive Beziehungen zu treuen Kunden
  • Herausragend bezüglich Fachkompetenz und Beratung
Kundengruppen
  • small/middle/large size pharmaceuticals
Referenzkunden
Mitgliedschaften
Mehr über uns
Eintrag erstellt: 17.09.2007, Letzte Änderung: 20.01.2009